You searched for Acalabrutinib - Page 5 of 26

Dr. Neil Kay and Dr. Sameer Parikh on Early-Stage Treatment with Acalabrutinib for Chronic Lymphocytic Leukemia (CLL)

October 28, 2021

In this interview, our own Dr. Brian Koffman spoke with Dr. Neil Kay, a Professor of Medicine and a hematologist at Mayo Clinic, and Dr. Sameer Parikh, a hematologist, an oncologist at the Mayo Clinic in Rochester, MN. They discussed why early-stage patients usually do not receive treatment and how that paradigm may be changing with the availability of new targeted therapies and better prognostic markers.

ASCO 2021: Dr. Matthew Davids on Acalabrutinib vs. Ibrutinib for Chronic Lymphocytic Leukemia (CLL)

October 8, 2021

At the annual meeting of the American Society of Clinical Oncology (ASCO) 2021, our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute in Boston, MA. They discussed new data from the ELEVATE R/R study, which is comparing acalabrutinib with ibrutinib head-to-head in high-risk patients with relapsed/refractory CLL and del(17p) or del(11q).

ASCO 2021 Top Pick #12: Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN Four-Year Follow Up

October 4, 2021

While hardly groundbreaking, the four-year follow-up data of the ELEVATE-TN trial affirms our confidence that acalabrutinib is a strong choice for frontline therapy in CLL.

ASCO 2021 Top Pick #1: First Results of a Head-To-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia Patients

October 4, 2021

Does the increased selectivity of the Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib (Aca) compared to ibrutinib (Ib) improve tolerability while maintaining efficacy?

ASH 2020: Dr. Paolo Ghia Discusses the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia or CLL

March 1, 2021

During ASH 2020, Dr. Paolo Ghia discussed the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory CLL. Dr. Ghia presented the final analyses of the ASCEND trial after nearly two years of follow-up. Acalabrutinib was the clear winner.

ASH 2020: Dr. Jennifer Brown on Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib

February 8, 2021

ASH 2020: Dr. Jennifer Brown on cardiovascular events in patients with chronic lymphocytic leukemia (CLL) treated with acalabrutinib

Update on CALAVI Phase II Trials for Acalabrutinib in Patients Hospitalized with Respiratory Symptoms of COVID-19

January 4, 2021

There has been much excitement about the possibility that BTK inhibitors such as ibrutinib or acalabrutinib might improve outcomes in COVID-19 for all patients ever since Dr. Treon published a retrospective

ASCO 2020 “Top 12” #2: Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability

August 20, 2020

#2 At virtual ASCO 2020, Dr. John Byrd led a group of researchers to report the latest from the first phase 2 study of acalabrutinib, ACE-CL-001 (NCT02029443), a next-generation BTK inhibitor, which is now approved for CLL patients, both treatment-naïve as well as those with relapsed/refractory disease.

ASH 2019: Dr Deborah Stephens on ARQ 531, a reversible BTK inhibitor to treat CLL that is no longer responding to ibrutinib or acalabrutinib, and maybe more.

June 15, 2020

ASH 2019: Dr Deborah Stephens on ARQ 531, a reversible BTK inhibitor to treat CLL that is no longer responding to ibrutinib or acalabrutinib, and maybe more.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Acalabrutinib – Page 5

Dr. Neil Kay and Dr. Sameer Parikh on Early-Stage Treatment with Acalabrutinib for Chronic Lymphocytic Leukemia (CLL)

ASCO 2021: Dr. Matthew Davids on Acalabrutinib vs. Ibrutinib for Chronic Lymphocytic Leukemia (CLL)

ASCO 2021 Top Pick #12: Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN Four-Year Follow Up

ASCO 2021 Top Pick #1: First Results of a Head-To-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia Patients

ASH 2020: Dr. Paolo Ghia Discusses the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia or CLL

ASH 2020: Dr. Jennifer Brown on Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib

Update on CALAVI Phase II Trials for Acalabrutinib in Patients Hospitalized with Respiratory Symptoms of COVID-19

ASCO 2020 “Top 12” #2: Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability

ASH 2019: Dr Deborah Stephens on ARQ 531, a reversible BTK inhibitor to treat CLL that is no longer responding to ibrutinib or acalabrutinib, and maybe more.

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT